< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
